Top Cannabis Investment News, Member Posts, Cannabis Investment Daily Indices and more!

3yrs ago Cannabis blunttruthlaw Views: 419

Welcome back to The Week in Weed, your Friday look at what’s happening in the world of legalized marijuana.

We begin with the claim that the Justice Department brought antitrust actions against cannabis companies due to Attorney General Bill Barr’s antipathy towards the industry.  The state of New Jersey is contemplating decriminalization, and Montana may have cannabis on the ballot.  The city of Denver gets into the R&D business.  Should the FDA issue a CBD rule quickly?  Some consumer groups say no.  Medical marijuana is now permitted to those on parole or probation.  And finally, we have an update on the Oklahoma fake email story!

antitrust and marijuana

DOJ attorney John Elias testified this week that the department was improperly investigating cannabis companies for antitrust violations. Video of the hearing is available here.  Written testimony is available here.  The DOJ’s Office of Professional Responsibility looked into the matter earlier this month and found no evidence of wrongdoing.  The memorandum is available here (subscription required).

new jersey

New Jersey is considering decriminalizing marijuana possession.  The state Assembly recently passed a bill substituting a fine for arrest for possession of up to two ounces of marijuana.  The bill now moves to the state Senate, where opinions against the legislation have recently shifted.

montana

New Approach Montana submitted over 130,000 signatures in support of two ballot initiatives to legalize and regulate adult-use cannabis in the state.  This is far above the number of signatures needed to put the measures before the voters, so it seems likely that they will make the November ballot.

research & development

The city of Denver awarded its first license for medical marijuana R&D.  MedPharm hopes to start work on its first project, studying marijuana’s effect on Alzheimer’s and dementia, by the end of 2020.

cbd rule

For years, the hemp and CBD industries have been waiting impatiently for the Food and Drug Administration to issue regulations on cannabidiol.  Now several consumer groups are suggesting they need to wait a bit longer.  The groups sent a joint letter to members of Congress, urging them not to push the FDA to issue regulations, as their attention has been diverted due to the pandemic.

pennsylvania

The Pennsylvania Supreme Court struck down a county law forbidding the use of medical marijuana by those on probation or parole.  The unanimous decision applies throughout the state.

and finally

Regular readers of this column will doubtless recall that the general counsel of the Oklahoma Department of Health sent herself threatening emails, which she claimed were from cannabis advocates.  She’s now been suspended from practicing law (subscriptoin required) for one year.  You just can’t make this stuff up.

Stay safe and be well everyone – we’ll see you next week!


Today's Cannabis Investment Headlines:

Log In for More
Access Over 250K+ Industry Headlines, Posts and Updates
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.